Specialising in cross-border equity transactions, Cooley (UK) LLP has built a strong track record advising on IPOs, follow-on offerings and private placements across major US and European exchanges. The firm is particularly active on mandates for high-growth, founder-led and life sciences businesses targeting US listings. Team head Claire Keast-Butler is valued by clients for her ability to handle London Main Market transactions as well as dual-listings in the US. Courtney Thorne is singled out for her experience in the life sciences sector and often advises foreign private issuers with mandates in the US.
Legal 500 Editorial commentary
Testimonials
Collated independently by Legal 500 research team.
‘Very strong, good access to US advice.'
Key clients
- Faron Pharmaceuticals
- Silence Therapeutics
- HOOKIPA Pharma
- Autolus
- Immunocore
- Tectonic Therapeutic
- Scancell
- Allergy Therapeutics
- Bicycle Therapeutics
- Janux Therapeutics
Work highlights
Advised Autolus Therapeutics on their strategic collaboration with BioNTech, sale of $200 million of Autolus’ American depositary shares, and its $350 million underwritten offering.
Advised Immunocore on its historic $402.5 million convertible notes offering.
Advised Bicycle Therapeutics on its $555.5 million private placement offering.
Lawyers
Leading partners
The strongest partners in their field, leading on market-leading deals and endorsed by peers and clients alike.
Practice head
Claire Keast-Butler
Other key lawyers
Courtney Thorne; Simon Aimes